Jeffrey Harris

Dr. Jeffrey Harris

Denali Therapeutics
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AAAnnie Arguello
Annie Arguello
CMCathal S. Mahon
Cathal S. Mahon
MCMeredith E.K. Calvert
Meredith E.K. Calvert
DCDarren Chan
Darren Chan
JDJason C. Dugas
Jason C. Dugas
MKMihalis S. Kariolis
Mihalis S. Kariolis
Delivery of biotherapeutics across the blood–brain barrier (BBB) is a challenge. Many approaches fuse biotherapeutics to platforms that bind the transferrin receptor (TfR), a brain endothelial cell target, to facilitate receptor-mediated transcytosis across the BBB. Here, we characterized the pharmacological behavior of two distinct TfR-targeted platforms fused to iduronate 2-sulfatase (IDS), a lysosomal enzyme deficient in mucopolysaccharidosis type II (MPS II), and compared the relative brain exposures and functional activities of both approaches in mouse models. IDS fused to a moderate-affinity, monovalent TfR-binding enzyme transport vehicle (ETV:IDS) resulted in widespread brain exposure, internalization by parenchymal cells, and significant substrate reduction in the CNS of an MPS II mouse model. In contrast, IDS fused to a standard high-affinity bivalent antibody (IgG:IDS) resulted in lower brain uptake, limited biodistribution beyond brain endothelial cells, and reduced brain substrate reduction. These results highlight important features likely to impact the clinical development of TfR-targeting platforms in MPS II and potentially other CNS diseases.

1 December 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JHJeffrey Harris
Jeffrey Harris
CCChristopher R. Cabanski
Christopher R. Cabanski
HSHeleen Scheerens
Heleen Scheerens
DSDivya Samineni
Divya Samineni
MBMary S. Bradley
Mary S. Bradley
MMMarcus Maurer
Marcus Maurer

8 October 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
AAAnnie Arguello
Annie Arguello
RMRené Meisner
René Meisner
ETElliot R. Thomsen
Elliot R. Thomsen
HNHoang N. Nguyen
Hoang N. Nguyen
RRRitesh Ravi
Ritesh Ravi
PSPascal E. Sanchez
Pascal E. Sanchez
Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of glycosaminoglycans (GAGs) throughout the body. Treatment of MPS II remains a considerable challenge as current enzyme replacement therapies do not adequately control many aspects of the disease, including skeletal and neurological manifestations. We developed an IDS transport vehicle (ETV:IDS) that is engineered to bind to the transferrin receptor; this design facilitates receptor-mediated transcytosis of IDS across the blood-brain barrier and improves its distribution into the brain while maintaining distribution to peripheral tissues. Here we show that chronic systemic administration of ETV:IDS in a mouse model of MPS II reduced levels of peripheral and central nervous system GAGs, microgliosis, and neurofilament light chain, a biomarker of neuronal injury. Additionally, ETV:IDS rescued auricular and skeletal abnormalities when introduced in adult MPS II mice. These effects were accompanied by improvements in several neurobehavioral domains, including motor skills, sensorimotor gating, and learning and memory. Together, these results highlight the therapeutic potential of ETV:IDS for treating peripheral and central abnormalities in MPS II. DNL310, an investigational ETV:IDS molecule, is currently in clinical trials as a potential treatment for patients with MPS II.

Verified
Journal Article
Open access
PDF file
Akhil BhallaAkhil Bhalla
Akhil Bhalla
RRRitesh Ravi
Ritesh Ravi
MFMeng Fang
Meng Fang
AAAnnie Arguello
Annie Arguello
SDSonnet S. Davis
Sonnet S. Davis
MEMaria L. Escolar
Maria L. Escolar
Mucopolysaccharidosis type II is a lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS) and characterized by the accumulation of the primary storage substrate, glycosaminoglycans (GAGs). Understanding central nervous system (CNS) pathophysiology in neuronopathic MPS II (nMPS II) has been hindered by the lack of CNS biomarkers. Characterization of fluid biomarkers has been largely focused on evaluating GAGs in cerebrospinal fluid (CSF) and the periphery; however, GAG levels alone do not accurately reflect the broad cellular dysfunction in the brains of MPS II patients. We utilized a preclinical mouse model of MPS II, treated with a brain penetrant form of IDS (ETV:IDS) to establish the relationship between markers of primary storage and downstream pathway biomarkers in the brain and CSF. We extended the characterization of pathway and neurodegeneration biomarkers to nMPS II patient samples. In addition to the accumulation of CSF GAGs, nMPS II patients show elevated levels of lysosomal lipids, neurofilament light chain, and other biomarkers of neuronal damage and degeneration. Furthermore, we find that these biomarkers of downstream pathology are tightly correlated with heparan sulfate. Exploration of the responsiveness of not only CSF GAGs but also pathway and disease-relevant biomarkers during drug development will be crucial for monitoring disease progression, and the development of effective therapies for nMPS II.

Verified
Journal Article
Open access
PDF file
JWJunhua Wang
Junhua Wang
Akhil BhallaAkhil Bhalla
Akhil Bhalla
JUJulie C. Ullman
Julie C. Ullman
MFMeng Fang
Meng Fang
RRRitesh Ravi
Ritesh Ravi
Giuseppe AstaritaGiuseppe Astarita
Giuseppe Astarita
We recently developed a blood–brain barrier (BBB)-penetrating enzyme transport vehicle (ETV) fused to the lysosomal enzyme iduronate 2-sulfatase (ETV:IDS) and demonstrated its ability to reduce glycosaminoglycan (GAG) accumulation in the brains of a mouse model of mucopolysaccharidosis (MPS) II. To accurately quantify GAGs, we developed a plate-based high-throughput enzymatic digestion assay coupled with liquid chromatography–tandem mass spectrometry (LC-MS/MS) to simultaneously measure heparan sulfate and dermatan sulfate derived disaccharides in tissue, cerebrospinal fluid (CSF) and individual cell populations isolated from mouse brain. The method offers ultra-high sensitivity enabling quantitation of specific GAG species in as low as 100,000 isolated neurons and a low volume of CSF. With an LOD at 3 ng/mL and LLOQs at 5–10 ng/mL, this method is at least five times more sensitive than previously reported approaches. Our analysis demonstrated that the accumulation of CSF and brain GAGs are in good correlation, supporting the potential use of CSF GAGs as a surrogate biomarker for brain GAGs. The bioanalytical method was qualified through the generation of standard curves in matrix for preclinical studies of CSF, demonstrating the feasibility of this assay for evaluating therapeutic effects of ETV:IDS in future studies and applications in a wide variety of MPS disorders.

1 December 1994 in Physica C: Superconductivity and its Applications
Verified
Journal Article
Closed access
YYY.F. Yan
Y.F. Yan
JHJeffrey Harris
Jeffrey Harris
NON.P. Ong
N.P. Ong